1-(4-氨基-3-氟)苯基-2-(N,N-二甲氨基)甲基咪唑 | 218301-68-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(4-氨基-3-氟)苯基-2-(N,N-二甲氨基)甲基咪唑
• 英文名称: 1-(4-amino-3-fluoro)phenyl-2-(N,N-dimethylamino)methylimidazole
• 英文别名: 2-fluoro-4-[(2-dimethylaminomethyl)imidazol-1-yl]aniline；4-[(2'-dimethylaminomethyl)imidazol-1'-yl]-2-fluoroaniline；4-(2-Dimethylaminomethyl-imidazol-1-yl)-2-fluoro-phenylamine；4-(2-dimethylaminomethyl-imidazol-1-yl)-2-fluorophenylamine；2-fluoro-4-[(2-dimethylaminomethyl)-imidazol-1-yl]-aniline；4-[2-[(dimethylamino)methyl]imidazol-1-yl]-2-fluoroaniline
• CAS: 218301-68-9
• 化学式: C₁₂H₁₅FN₄
• 分子量: 234.276
• InChiKey: QQNBPZJMJAYORR-UHFFFAOYSA-N

物化性质

• 熔点：
  121-122 °C
• 沸点：
  387.7±52.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  47.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(4-氨基-3-氟)苯基-2-(N,N-二甲氨基)甲基咪唑 在 4-二甲氨基吡啶 、 acetoxyhydroxamic acid 、 potassium tert-butylate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 雷扎沙班
  参考文献：
  名称：

  Discovery of 1-(3‘-Aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor

  摘要：

  Modification of a series of pyrazole factor Xa inhibitors to incorporate an aminobenzisoxazole as the P(1) ligand resulted in compounds with improved selectivity for factor Xa relative to trypsin and plasma kallikrein. Further optimization of the P(4) moiety led to compounds with enhanced permeability and reduced protein binding. The SAR and pharmacokinetic profile of this series of compounds is described herein. These efforts culminated in 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide (11d), a potent, selective, and orally bioavailable inhibitor of factor Xa. On the basis of its excellent in vitro potency and selectivity profile, high free fraction in human plasma, good oral bioavailability, and in vivo efficacy in antithrombotic models, the HCl salt of this compound was selected for clinical development as razaxaban (DPC 906, BMS-561389).

  DOI：

  10.1021/jm0497949
• 作为产物：
  描述：

  4-溴-2-氟苯胺 、 2-[(二甲氨基)甲基]咪唑 生成 1-(4-氨基-3-氟)苯基-2-(N,N-二甲氨基)甲基咪唑
  参考文献：
  名称：

  Efficient ligand-mediated ullmann coupling of anilnies and azoles

  摘要：

  本发明提供了制备苯基取代咪唑的方法。该方法利用了一种高效的配体加速的乌尔曼偶联反应，将苯胺与咪唑偶联。偶联产物可用于制备因子Xa抑制剂。

  公开号：

  US20020099225A1
• 作为试剂：
  描述：

  2-(3-cyano-4-fluoro-phenyl)-5-trifluoromethyl-2H-pyrazole-3-carbonyl chloride 、 1-(4-氨基-3-氟)苯基-2-(N,N-二甲氨基)甲基咪唑 在 1-(4-氨基-3-氟)苯基-2-(N,N-二甲氨基)甲基咪唑 作用下， 以85的产率得到1-(3'-cyano-4'-fluorophenyl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide
  参考文献：
  名称：

  J. Med. Chem. 2005, 48, 1729-1744

  摘要：

  DOI：

文献信息

• Dicarboxamide derivatives
  申请人：Boehringer Markus

  公开号：US20060106016A1

  公开（公告）日：2006-05-18

  The invention is concerned with novel dicarboxamide derivatives of formula (I) wherein A, B, R c , D and E are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.

  这项发明涉及式(I)的新颖二羧酰胺衍生物，其中A、B、Rc、D和E如描述和索赔中所定义，并且其生理上可接受的盐。这些化合物抑制凝血因子Xa，可用作药物。
• Guanidine mimics as factor Xa inhibitors
  申请人：DuPont Pharmaceuticals Company

  公开号：US06339099B1

  公开（公告）日：2002-01-15

  The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein rings D—E represent guanidine mimics, which are useful as inhibitors of factor Xa.

  本申请描述了含氮杂环化合物及其衍生物的化学式I：或其药用可接受的盐形式，其中环D—E代表胍嘧啶模拟物，这些化合物可作为凝血因子Xa的抑制剂。
• Beta-aminoacid-derivatives as factor Xa inhibitors
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1571154A1

  公开（公告）日：2005-09-07

  The present invention relates to compounds of the formula I, in which R0 ; R1 ; R2 ; R3 ; R4; R5, R6, Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及式I的化合物，其中R0; R1; R2; R3; R4; R5，R6，Q; V，G和M具有索赔中指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如，适用于治疗和预防心血管疾病，如血栓栓塞疾病或再狭窄。它们是血凝酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，通常可应用于存在因子Xa和/或因子VIIa的不良活性或对其进行抑制的治疗或预防的情况。此外，本发明涉及式I化合物的制备方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。
• Carbocyclic fused cyclic amines
  申请人：Boehringer Markus

  公开号：US20070112012A1

  公开（公告）日：2007-05-17

  The invention is concerned with novel carbocyclyl fused cyclic amines of formula (I) wherein A, X 1 to X 3 , Y 1 to Y 3 , Z, R 1 , R 2 , m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.

  该发明涉及化学式(I)中的新型碳环融合的环胺，其中A、X1至X3、Y1至Y3、Z、R1、R2、m和n的定义如描述和权利要求中所定义，以及其生理学上可接受的盐。这些化合物抑制凝血因子Xa，可以用作药物。
• Heteroarylacetamide inhibitors of factor Xa
  申请人：Boehringer Markus

  公开号：US20060142362A1

  公开（公告）日：2006-06-29

  The invention is concerned with novel heteroarylacetamides of formula (I) R d —C(O)—N(R e )—R c —CH 2 —C(O)—N(R a )(R b )   (I) wherein R a to R e are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.

  这项发明涉及式(I)的新异杂芳乙酰胺Rd—C(O)—N(Re)—Rc—CH2—C(O)—N(Ra)(Rb)，其中Rato Re的定义如描述和索赔中所述，以及其生理上可接受的盐。这些化合物抑制凝血因子Xa，可用作药物。